196 related articles for article (PubMed ID: 11731420)
1. Arzoxifene, a new selective estrogen receptor modulator for chemoprevention of experimental breast cancer.
Suh N; Glasebrook AL; Palkowitz AD; Bryant HU; Burris LL; Starling JJ; Pearce HL; Williams C; Peer C; Wang Y; Sporn MB
Cancer Res; 2001 Dec; 61(23):8412-5. PubMed ID: 11731420
[TBL] [Abstract][Full Text] [Related]
2. A new antiestrogen, 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-indol-5-ol hydrochloride (ERA-923), inhibits the growth of tamoxifen-sensitive and -resistant tumors and is devoid of uterotropic effects in mice and rats.
Greenberger LM; Annable T; Collins KI; Komm BS; Lyttle CR; Miller CP; Satyaswaroop PG; Zhang Y; Frost P
Clin Cancer Res; 2001 Oct; 7(10):3166-77. PubMed ID: 11595711
[TBL] [Abstract][Full Text] [Related]
3. Effects of 3-phenyl-4-[[4-[2-(1-piperidinyl)ethoxy]phenyl]methyl]- 2H-1-benzopyran-7-ol (CHF 4056), a novel nonsteroidal estrogen agonist/antagonist, on reproductive and nonreproductive tissue.
Galbiati E; Caruso PL; Amari G; Armani E; Ghirardi S; Delcanale M; Civelli M
J Pharmacol Exp Ther; 2002 Mar; 300(3):802-9. PubMed ID: 11861784
[TBL] [Abstract][Full Text] [Related]
4. Discovery and synthesis of [6-hydroxy-3-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-2-(4-hydroxyphenyl)]b enzo[b]thiophene: a novel, highly potent, selective estrogen receptor modulator.
Palkowitz AD; Glasebrook AL; Thrasher KJ; Hauser KL; Short LL; Phillips DL; Muehl BS; Sato M; Shetler PK; Cullinan GJ; Pell TR; Bryant HU
J Med Chem; 1997 May; 40(10):1407-16. PubMed ID: 9154963
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological actions of a novel, potent, tissue-selective benzopyran estrogen.
Galbiati E; Caruso PL; Amari G; Armani E; Ghirardi S; Delcanale M; Civelli M
J Pharmacol Exp Ther; 2002 Oct; 303(1):196-203. PubMed ID: 12235251
[TBL] [Abstract][Full Text] [Related]
6. The effect of the new SERM arzoxifene on growth and gene expression in MCF-7 breast cancer cells.
Freddie CT; Larsen SS; Bartholomaeussen M; Lykkesfeldt AE
Mol Cell Endocrinol; 2004 Apr; 219(1-2):27-36. PubMed ID: 15149724
[TBL] [Abstract][Full Text] [Related]
7. Antioestrogenic and antitumour activities of a series of non-steroidal antioestrogens.
Wakeling AE; Valcaccia B
J Endocrinol; 1983 Dec; 99(3):455-64. PubMed ID: 6644236
[TBL] [Abstract][Full Text] [Related]
8. Effects of a new clinically relevant antiestrogen (GW5638) related to tamoxifen on breast and endometrial cancer growth in vivo.
Dardes RC; O'Regan RM; Gajdos C; Robinson SP; Bentrem D; De Los Reyes A; Jordan VC
Clin Cancer Res; 2002 Jun; 8(6):1995-2001. PubMed ID: 12060645
[TBL] [Abstract][Full Text] [Related]
9. Raloxifene is a tissue-selective agonist/antagonist that functions through the estrogen receptor.
Fuchs-Young R; Glasebrook AL; Short LL; Draper MW; Rippy MK; Cole HW; Magee DE; Termine JD; Bryant HU
Ann N Y Acad Sci; 1995 Jun; 761():355-60. PubMed ID: 7625735
[No Abstract] [Full Text] [Related]
10. Molecular determinants of tissue selectivity in estrogen receptor modulators.
Grese TA; Sluka JP; Bryant HU; Cullinan GJ; Glasebrook AL; Jones CD; Matsumoto K; Palkowitz AD; Sato M; Termine JD; Winter MA; Yang NN; Dodge JA
Proc Natl Acad Sci U S A; 1997 Dec; 94(25):14105-10. PubMed ID: 9391160
[TBL] [Abstract][Full Text] [Related]
11. Effects of oral estrogen, raloxifene and arzoxifene on gene expression in serotonin neurons of macaques.
Bethea CL; Mirkes SJ; Su A; Michelson D
Psychoneuroendocrinology; 2002 May; 27(4):431-45. PubMed ID: 11911997
[TBL] [Abstract][Full Text] [Related]
12. The combination of the rexinoid, LG100268, and a selective estrogen receptor modulator, either arzoxifene or acolbifene, synergizes in the prevention and treatment of mammary tumors in an estrogen receptor-negative model of breast cancer.
Liby K; Rendi M; Suh N; Royce DB; Risingsong R; Williams CR; Lamph W; Labrie F; Krajewski S; Xu X; Kim H; Brown P; Sporn MB
Clin Cancer Res; 2006 Oct; 12(19):5902-9. PubMed ID: 17020999
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and pharmacology of conformationally restricted raloxifene analogues: highly potent selective estrogen receptor modulators.
Grese TA; Pennington LD; Sluka JP; Adrian MD; Cole HW; Fuson TR; Magee DE; Phillips DL; Rowley ER; Shetler PK; Short LL; Venugopalan M; Yang NN; Sato M; Glasebrook AL; Bryant HU
J Med Chem; 1998 Apr; 41(8):1272-83. PubMed ID: 9548817
[TBL] [Abstract][Full Text] [Related]
14. Tissue selective action of tamoxifen methiodide, raloxifene and tamoxifen on creatine kinase B activity in vitro and in vivo.
Sömjen D; Waisman A; Kaye AM
J Steroid Biochem Mol Biol; 1996 Dec; 59(5-6):389-96. PubMed ID: 9010344
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of estrogen-stimulated growth of uterine leiomyomas by selective estrogen receptor modulators.
Fuchs-Young R; Howe S; Hale L; Miles R; Walker C
Mol Carcinog; 1996 Nov; 17(3):151-9. PubMed ID: 8944075
[TBL] [Abstract][Full Text] [Related]
16. Characterization of the "estrogenicity" of tamoxifen and raloxifene in HepG2 cells: regulation of gene expression from an ERE controlled reporter vector versus regulation of the endogenous SHBG and PS2 genes.
Barkhem T; Andersson-Ross C; Höglund M; Nilsson S
J Steroid Biochem Mol Biol; 1997 May; 62(1):53-64. PubMed ID: 9366498
[TBL] [Abstract][Full Text] [Related]
17. Effects of the new selective estrogen receptor modulator LY353381.HCl (Arzoxifene) on human endometrial cancer growth in athymic mice.
Dardes RC; Bentrem D; O'Regan RM; Schafer JM; Jordan VC
Clin Cancer Res; 2001 Dec; 7(12):4149-55. PubMed ID: 11751515
[TBL] [Abstract][Full Text] [Related]
18. Effect of the selective estrogen receptor modulator arzoxifene on repopulation of hormone-responsive breast cancer xenografts between courses of chemotherapy.
Wu L; Tannock IF
Clin Cancer Res; 2005 Nov; 11(22):8195-200. PubMed ID: 16299252
[TBL] [Abstract][Full Text] [Related]
19. Prevention and treatment of experimental breast cancer with the combination of a new selective estrogen receptor modulator, arzoxifene, and a new rexinoid, LG 100268.
Suh N; Lamph WW; Glasebrook AL; Grese TA; Palkowitz AD; Williams CR; Risingsong R; Farris MR; Heyman RA; Sporn MB
Clin Cancer Res; 2002 Oct; 8(10):3270-5. PubMed ID: 12374698
[TBL] [Abstract][Full Text] [Related]
20. Structure-activity relationships for a family of benzothiophene selective estrogen receptor modulators including raloxifene and arzoxifene.
Overk CR; Peng KW; Asghodom RT; Kastrati I; Lantvit DD; Qin Z; Frasor J; Bolton JL; Thatcher GR
ChemMedChem; 2007 Oct; 2(10):1520-6. PubMed ID: 17654759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]